Fixed ratio drug combination treatments for solid tumors

1. A method to treat an advanced solid cancer in a human subject, said method comprising administering to said subject a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine, wherein said fixed, non-antagonistic molar ratio is maintained in the plasma for at least about 4 hours,

wherein said fixed, non-antagonistic molar ratio of irinotecan and floxuridine is about 1:1 and is encapsulated in liposomes,

wherein each dose of the composition is administered intravenously to said human subject over a period of 30 minutes to three hours, wherein the dose contains less than 0.0004 moles/m 2 of floxuridine, and wherein floxuridine is administered at a level not greater than 0.0008 moles/m 2 /month, and

wherein said advanced solid cancer is a gastric cancer, a renal cancer, a breast cancer, a colon cancer, an esophageal cancer, a prostate cancer, a pancreatic cancer, an ovarian cancer, an osteosarcoma, or a sphenoid sinus cancer.

2. The method of claim 1 , wherein said fixed non-antagonistic molar ratio is maintained for at least about 8 hours.

3. The method of claim 1 , wherein said fixed non-antagonistic molar ratio is maintained for at least about 16 hours.

4. The method of claim 1 , wherein said treatment is a first line treatment or said subject has previously undergone at least one multi-agent anticancer regimen.

5. The method of claim 1 , wherein each dose of said composition is administered in about 90 minutes.

6. The method of claim 1 , wherein each dose of floxuridine contains 0.0003 moles/m 2 .

7. The method of claim 1 , wherein floxuridine is administered at 0.0006 moles/m 2 /month.